

29 January 2013

ASX Limited  
Adviser, Issuers (Sydney)  
Exchange Centre  
20 Bridge Street  
Sydney NSW 2000

Attention: Stephanie Yong

By email: [stephanie.yong@asx.com.au](mailto:stephanie.yong@asx.com.au)

Dear Ms Yong,

**Request for Trading Halt**

Pharmaxis Ltd (**Pharmaxis**) requests an immediate trading halt of its securities pending the completion, and announcement of the outcome, of the review of Bronchitol<sup>®</sup> for the treatment of cystic fibrosis by the Pulmonary-Allergy Drug Advisory Committee or "PADAC", an independent expert advisory panel to the U.S. Food and Drug Administration.

The PADAC review meeting is being held on Wednesday 30 January 2013 (U.S. time). The briefing information for the PADAC meeting has been released publicly overnight on the FDA website in accordance with the FDA's standard process and the Company is not in a position to comment on the briefing materials until the meeting process has been concluded. The Company's announcement in relation to the outcome of the review process is expected to be made on the morning of Thursday, 31 January 2013.

Pharmaxis requests that the trading halt apply from the commencement of trading on 29 January 2013 and continue until the earlier of Pharmaxis making an announcement to the market regarding the outcome of the review process or the commencement of trading on Thursday 29 January 2013.

In accordance with ASX Listing Rule 17.1, Pharmaxis confirms that it is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market about the trading halt.

Yours sincerely



David McGarvey  
Chief Financial Officer/ Company Secretary